New drug pricing policy proposes bringing all essential medicines under price control, but makes them expensive After years of dilly-dallying and several Supreme Court reminders, the Centre has proposed to bring all essential drugs under price control. But the policy is nothing but hogwash. Its pricing mechanism would make essential medicines out of reach for most people. Public health experts have termed the draft National Pharmaceutical Pricing Policy of 2011 a...
More »SEARCH RESULT
Prices of 348 essential drugs to be controlled
-The Times of India The Centre on Thursday responded to the Supreme Court's concern over spiralling prices of essential medicines and promised to make all-out efforts to put under strict price control regime all the 348 drugs included in the National List of Essential Medicines (NLEM), 2011. A bench comprising Justices G S Singhvi and S J Mukhopadhaya had, in the last hearing, expressed concern over the shrinking list of medicines under...
More »Investing in health
-The Hindu The High Level Expert Group of the Planning Commission on Universal Health Coverage for India has laid out a clear road map: it is to provide access to affordable, accountable, and appropriate health services for all citizens in a meaningful time frame. Free India adopted the goal of preventive and curative care for all, as recommended by the Bhore Committee in 1946. But it faltered and failed to raise...
More »Medicines: For Saving Life or For Superprofits? by Bharat Dogra
Will patent rights be used only for ensuring the legitimate interests of pharmaceutical companies, or will these be used in an exaggerated and unjust way to deprive patients of their right to life? This crucial question, which has been debated time and again in the context of the significant case of Glivec, an anti-cancer drug, has now reached a critical stage. It may be pointed out here that as early as...
More »Affordable medicine
-The Business Standard It appears a committee headed by Planning Commission member Arun Maira examining the case for continued unrestricted foreign direct investment (FDI) in the pharmaceutical industry has opted to oppose the move to change the present regime. The only concession it is willing to make to the health and commerce ministries’ demand that approval of such investment be routed through the Foreign Investment Promotion Board is to ask for...
More »